nach oben

Erschienen in:

01.11.2006 | Original Paper

Dopamine D₂ Receptor Polymorphisms in Inflammatory Bowel Disease and the Refractory Response to Treatment

verfasst von: F. Magro, E. Cunha, F. Araujo, E. Meireles, P. Pereira, M. Dinis-Ribeiro, F. Tavarela Veloso, R. Medeiros, P. Soares-da-Silva

Erschienen in: Digestive Diseases and Sciences | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

Dopamine and its receptors may be involved in inflammatory reaction. The availability of this molecule depends on its receptors. The DRD2 gene, which codifies for the D2 dopamine receptor, has several polymorphisms. In this study, the DRD2 TaqIA polymorphism, which confers a decreased receptor density, was evaluated in 313 individuals including 220 inflammatory bowel disease patients (143 patients with Crohn’s disease and 77 with ulcerative colitis) and in 93 healthy blood donors. The analysis was carried out by PCR-RFLP techniques. The frequencies of A ₁ A ₁ and A ₂ A ₂ genotypes were similar among Crohn’s disease, ulcerative colitis patients, and health controls. Also, the genotype frequency was similar in different groups of disease localization, behavior, and age of disease onset. However, the Crohn’s disease patients carriers of A ₂ A ₂ genotype showed a lower risk for development refractory Crohn’s disease (37 out 65) than A ₁ A ₁ and A ₁ A ₂ carriers (28 out of 65) [(OR=0.4, 95% CI 0.21–0.87; p=0.02)]. Our results support an involvement of the dopamine receptor in inflammatory bowel disease and suggest a new potential target for therapy in refractory Crohn’s disease patients.

Groux H, Powrie F (1999) Regulatory T cells and inflammatory bowel disease. Immunol Today 20:442–445PubMedCrossRef

Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, Ehrhardt R, Neurath M (1997) Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol Today 18:61–64PubMedCrossRef

Stangi J, Parkes M, Louis E (1996) Two stage genoma-with search in inflammatory bowel disease provides evidence for susceptibility loci on chromossoma 3,7 and 12. Nat Genet 14:199–202CrossRef

Hugot JP, Chamaillard M, Zouali H (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411:599–603PubMedCrossRef

Ogura Y, Bonen DK, Inohara N (2001) A frameshift mutation in NOD2 associated with susceptibility to Cohn’s disease. Nature 411:603–606PubMedCrossRef

Ader S, Felton D, Cohn N (1990) Interactions between the brain and the immune system. Annu Rev Pharmacol Toxicol 30:561–602PubMedCrossRef

Basu S, Dasgupta PS (2000) Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol 102:113–124PubMedCrossRef

McKenna F, Mclaughlin PJ, Lweis BJ, Sibbring GC, Cumerson JA, Bowen-Jones D (2002) Dopamine receptor expression on human T and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol 132:34–40PubMedCrossRef

Ricci A, Vegilio F, Amenta F (1995) Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with 3H-7-OH-DPAT. J Neuroimmunol 58:139–144PubMedCrossRef

10.

Bergquist J, Tarkowski A, Ekman R, Ewing A (1994) Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamines regulation of lymphocytes function via an autocrine loop. Proc Natl Acad Sci USA 91:12912–12916PubMedCrossRef

11.

Magro F, Vieira-Coelho MA, Fraga S, Serrao MP, Veloso FT, Ribeiro T, Soares-da-Silva P (2002) Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci 47:216–224PubMedCrossRef

12.

Magro F, Fraga S, Ribeiro T, Soares-da-Silva P (2004) Decreased availability of intestinal dopamine in transmural colitis may relate to inhibitory effects of interferon-gamma upon L-dopa uptake. Acta Physiol Scand 180:379–386PubMedCrossRef

13.

Harvey RF, Bradshaw JM (1980) A simple index of Crohn’s disease activity. Lancet 1(8167):514PubMedCrossRef

14.

Irvine EJ (1995) Usual therapy improves Crohn’s disease as measure a new disease activity index. McMaster Study Group. J Clin Gastroenterol 20:27–32PubMedCrossRef

15.

Truelove SC, Witts LJ (1995) Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 4947:1041–1048

16.

Munkholm P, Langholz E, Davidsen M, Binder V (1994) Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 35:360–362PubMed

17.

Potocnik U, Ferkolj I, Glavac D, Dean M (2004) Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn’s disease and ulcerative colitis. Genes and Immunity 5:530–539PubMedCrossRef

18.

Spitz MR, Shi H, Yang F, Hudmon KS, Jiang H, Chamberlain RM, Amos CI, Wan Y, Cinciripini P, Hong WK, Wu X (1998) Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 90:358–363PubMedCrossRef

19.

Niessner M, Volk BA (1995) Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reverse transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 101:428–435PubMedCrossRef

20.

Breese E, Braegger CP, Corrigan CJ (1993). Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunol Today 78:127–131

21.

Papadakis KA, Targan SR (2000) Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51:289–298PubMedCrossRef

22.

Peppelenbosch MP, Deventer SJ (2004) T cell apoptosis and inflammatory bowel disease. Gut 53:1556–1558PubMedCrossRef

23.

Ghosh MC, Mondal AC, Basu S, Banerjee S, Majumber J, Bhattacharya D, Dasgupta PA (2003) Dopamine inhibits cytokine release and expression of tyrosine kinases, LCK and Fyn in activated T cells. Int Immunopharmacol 3:1019–1026PubMedCrossRef

24.

Denny MF, Patai B, Strauss DB (2000) Differential T-cell antigen receptor signaling mediated by Src family kinases Lck and Fyn. Mol Cell Biol 20:1426–1435PubMedCrossRef

25.

Qian D, Weiss A (1997) T cell antigen receptor signal transduction. Curr Opin Cell Biol 9:205–212PubMedCrossRef

26.

Morikawa K, Oseko F, Morikawa S (1994) Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro. Clin Exp Immunol 95:514–518PubMedCrossRef

27.

Riskind PN, Massacesi L, Doolittle TH, Hauser SL (1991) The role of prolactin in autoimmune demyelination: suppression of experimental allergic encepalomyelitis by bromocriptine. Ann Neurol 29:542–547PubMedCrossRef

28.

Bergquist J, Josefsson E, Tarkowski A, Ekman R, Ewing A (1997) Measurements of catecholamine-mediated apoptosis of immunocompetent cells by capillary electrophoresis. Electrophoresis 18:1760–1766PubMedCrossRef

29.

Colombo C, Cosentino M, Marino F, Rasini E, Ossola M, Blandini F, Mangiagalli A, Samuele A, Ferrari M, Bombelli R, Lecchini S, Nappi G, Frigo G (2003) Dopaminergic modulation of apoptosis in human blood mononuclear cells: possible relevance of Parkinson’s disease. Ann N Y Acad Sci 1010:679–682PubMedCrossRef

30.

Figueroa FE, Carrion F, Martinnez ME, Rivero S, Mamani L (1997) Bromocriptine induces immunological changes related to disease parameters in rheumatoid arthritis. Br J Rheumatol 36:1022–1023PubMedCrossRef

31.

McMurray RW, Weidensaul D, Allen SH, Walker SE (1995) Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Reumatol 22:2084–2091

32.

Weber G, Frey H (1987) Treatment of psoriatic arthritis with bromocriptine. J Am Acad Dermatol 16:388–389PubMedCrossRef

33.

Kast RE, Altschuler EL (2001) Remission of Crohn’s disease on Bupropion. Gastroenterol 121:1260–1261CrossRef

34.

Bergquist J, Silberring J (1998) Identification of catecholamines in the immune system by electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom 12:683–688PubMedCrossRef

35.

Josefsson E, Bergquist J, Ekman R, Tarkowski A (1996) Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis. Immunology 88:140–146PubMedCrossRef

36.

Tsao CW, Lin YS, Cheng JT (1998) Inhibition of immune cell proliferation with haloporinol and relationship of tyrosine hydroxylase expression to immune cell growth. Life Sci 62:PL335–PL344CrossRef

37.

Ricci A, Bronzetti E, Felici L, Greco S, Amenta F (1998) Labeling of dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes with 3H7-OH-DPAT: a combined radioligand binding assay and immunochemical study. J Neuroimmunol 92:191–195PubMedCrossRef

38.

Ricci A, Bronzetti E, Mignini F, Tayebati SK, Zaccheo D, Amenta F (1999) Dopamine d1-like receptor subtypes in human peripheral blood lymphocytes. J Neuroimmunol 96:234–240PubMedCrossRef

39.

Levite M, Chowers Y, Ganor Y, Besser M, Hershkovits R, Cahalon L (2001) Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta 1 integrin function. Eur J Immunol 31:3504–3512PubMedCrossRef

40.

Civelli O, Buzow JR, Grandy DK (1993) Molecular diversity of dopamine receptors. Annu Rev Pharmacol Toxicol 32:281–307CrossRef

41.

Gingrich JA, Caron MG (1993) Recent advances in molecular biology of dopamine receptors. Annu Rev Neurosci 16:299–321PubMedCrossRef

42.

Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, Makam H, Reed L, Magenis RE, Civelli O (1989) The human D(2) dopamine receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet 45:778–785PubMed

43.

Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ (1991) Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psych 48:648–654

44.

Noble EP, St Jeor ST, Ritchie T, Syndulko K, St Jeor SC, Fitch RJ, Brunner RL, Sparkes RS (1994) D2 dopamine receptor gene and cigarette smoking: a reward gene? Med Hypotheses 42:257–260PubMedCrossRef

45.

Epstein LH, Wright SM, Paluch RA, Leddy JJ, Hawk LWJ, Jaroni JL, Saad FG, Crystal-Mansour S, Shields PG, Lerman C (2004) Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers. Am J Clin Nutr 80:82–88PubMed

Titel: Dopamine D2 Receptor Polymorphisms in Inflammatory Bowel Disease and the Refractory Response to Treatment
verfasst von: F. Magro
E. Cunha
F. Araujo
E. Meireles
P. Pereira
M. Dinis-Ribeiro
F. Tavarela Veloso
R. Medeiros
P. Soares-da-Silva
Publikationsdatum: 01.11.2006
Verlag: Kluwer Academic Publishers-Plenum Publishers
Erschienen in: Digestive Diseases and Sciences / Ausgabe 11/2006
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-006-9168-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2006

A Retrospective Search for Predictors of Clinical Response to Selective Granulocyte and Monocyte Apheresis in Patients With Ulcerative Colitis

Type 1 Autoimmune Hepatitis in Taiwan: Diagnosis Using the Revised Criteria of the International Autoimmune Hepatitis Group

Aspects of Digestive Tract Tumors in Down Syndrome: A Literature Review

ICAM-1 Signal Transduction in Cells Stimulated with Neutrophil Elastase

Allergen-Specific In Vitro Cytokine Production in Adult Patients with Eosinophilic Esophagitis